Continued good progress for VRUS in the clinic to be sure. But, how much more upside do we see for the stock at its ~$1.2B market cap, short of a buyout offer? I.e., would a partnership for any of its HCV nukes propel the stock materially higher from the current market cap?
Market Data 
Markets 
AI
